FLT3 and acute myeloid leukemia: It needs to be further estimated whether the combination of these two drugs might have a synergetic effect on AML patients with FLT3-ITD mutations, so we are going to carry out a clinical trial on gilteritinib and HHT for R/R AML patients with FLT3-ITD mutation.